drugset / Trial / NCT05155124
Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC
Phase 1
Unknown
6 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NaSingle-groupOpen-labelTreatment
Summary
This was a single-arm, prospective study to investigate the safety of cetuximab in combination with trifluridin tipiracil (TAS-102) in the third-line treatment of Chinese patients with RAS wild-type mCRC.
Timeline
- Start
- 2022-09
- Primary completion
- 2022-10
- Completion
- 2023-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | — |
| Subject | trifluridin tipiracil | Unknown | 30 mg/m2 | — |
| Subject | trifluridin tipiracil | Unknown | 35 mg/m2 | — |